Meta-Analysis:
Prognostic value of endoglin-assessed microvessel density in cancer patients: a systematic review and meta-analysis
Metrics: PDF 1957 views | HTML 3224 views | ?
Abstract
Jinguo Zhang1,2, Lingyun Zhang1,2, Qunbo Lin1,2, Weimin Ren1,2 and Guoxiong Xu1,2
1Center Laboratory, Jinshan Hospital, Fudan University, Shanghai 201508, China
2Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China
Correspondence to:
Guoxiong Xu, email: [email protected]
Keywords: cancer; CD105; disease-free survival; overall survival; prognosis
Received: July 17, 2017 Accepted: October 30, 2017 Published: December 21, 2017
ABSTRACT
Background: Endoglin (ENG, CD105), an auxiliary receptor for several TGF-β superfamily ligands, is constitutively expressed in tumor microvessels. The prognostic value of ENG-assessed microvessel density (MVD) has not been systemically analyzed. This meta-analysis reviews and evaluates the association between ENG expression and prognosis in cancer patients.
Materials and Methods: Thirty published studies involving in 3613 patients were included after searching of PubMed, Web of Science, and EMBASE. The pooled hazard ratios (HRs) and 95% confidence intervals (CIs) for overall survival (OS), disease-free survival (DFS), and cancer-specific survival (CSS) were calculated using random-effects models. The publication bias was detected by a Begg’s test and Egger’s test. The outcome stability was verified by sensitivity analysis.
Results: The high ENG-assessed MVD was significantly associated with poor OS (HR = 2.14, 95% CI 1.62–2.81; P < 0.001), DFS (HR = 3.23, 95% CI 2.10–4.95; P < 0.001), CSS (HR = 3.33, 95% CI 1.32–8.37; P < 0.001). Furthermore, subgroup analysis revealed that the association between the overexpression of ENG in tumor microvessels and the outcome endpoints (OS or DFS) were also significant in the Asians and Caucasians patients with different cancer types.
Conclusions: ENG of tumor microvessels is a predictor of poor OS, DFS and CSS and may be a prognostic marker of patients with cancer.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 23546